Stifel analyst Rick Wise raised the firm’s price target on Abbott to $125 from $110 and keeps a Buy rating on the shares, telling investors that management had "an encouragingly positive tone to start 2023" on the company’s earnings call. With the company starting off with high-single-digit organic sales growth guidance and $4.30-$4.50 EPS guidance that "basically brackets current consensus," the 2023 setup "also appears encouraging," the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABT:
- Abbott price target raised to $123 from $109 at Raymond James
- Abbott price target raised to $132 from $125 at Bernstein
- Abbott expects $2B in covid testing in FY23
- Abbott Delivers Better-than-Expected Q4 Earnings
- Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook